268 related articles for article (PubMed ID: 30568113)
1. Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab.
Senoo S; Ninomiya T; Makimoto G; Nishii K; Kano H; Watanabe H; Hata Y; Kubo T; Tanaka T; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Apr; 58(7):985-989. PubMed ID: 30568113
[TBL] [Abstract][Full Text] [Related]
2. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
[TBL] [Abstract][Full Text] [Related]
3. A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.
Watanabe H; Ohashi K; Nishii K; Seike K; Makimoto G; Hotta K; Maeda Y; Kiura K
Intern Med; 2019 Oct; 58(20):3033-3037. PubMed ID: 31292383
[TBL] [Abstract][Full Text] [Related]
4. Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
Roesel C; Kambartel K; Kopeika U; Berzins A; Voshaar T; Krbek T
Curr Oncol; 2019 Apr; 26(2):e270-e273. PubMed ID: 31043837
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
[TBL] [Abstract][Full Text] [Related]
6. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
[TBL] [Abstract][Full Text] [Related]
7. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
8. Case series of pleomorphic carcinomas of the lung treated with nivolumab.
Kanazu M; Uenami T; Yano Y; Nakatsubo S; Hosono Y; Ishijima M; Akazawa Y; Yamaguchi T; Urasaki K; Mori M; Yokota S
Thorac Cancer; 2017 Nov; 8(6):724-728. PubMed ID: 28881488
[TBL] [Abstract][Full Text] [Related]
9. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
10. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials.
Zhao B; Zhang W; Yu D; Xu J; Wei Y
Cancer Med; 2018 May; 7(5):1642-1659. PubMed ID: 29573217
[TBL] [Abstract][Full Text] [Related]
11. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y; Inui N; Karayama M; Imokawa S; Yamada T; Yokomura K; Asada K; Kusagaya H; Kaida Y; Matsuda H; Koshimizu N; Toyoshima M; Masuda M; Hayakawa H; Hozumi H; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Suda T
Int J Chron Obstruct Pulmon Dis; 2019; 14():1867-1877. PubMed ID: 31686799
[TBL] [Abstract][Full Text] [Related]
12. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
13. Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.
Yorozuya T; Taya T; Yasuda K; Nagano Y; Shioya M; Chiba H; Takahashi H
Thorac Cancer; 2020 Apr; 11(4):1090-1093. PubMed ID: 32045109
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab.
Li P; Che G
Cancer Immunol Immunother; 2020 Mar; 69(3):489. PubMed ID: 31807877
[No Abstract] [Full Text] [Related]
15. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Ide M; Tanaka K; Sunami S; Asoh T; Maeyama T; Tsuruta N; Nakanishi Y; Okamoto I
Thorac Cancer; 2018 Nov; 9(11):1519-1521. PubMed ID: 30152594
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Episodes of Nivolumab-Induced Pneumonitis after Nivolumab Discontinuation and the Time Course of Carcinoembryonic Antigen Levels: A Case of a 58-Year-Old Woman with Non-Small Cell Lung Cancer.
de Jong C; Peters BJM; Schramel FMNH
Chemotherapy; 2018; 63(5):272-277. PubMed ID: 30572331
[TBL] [Abstract][Full Text] [Related]
17. A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Jodai T; Yoshida C; Sato R; Kakiuchi Y; Sato N; Iyama S; Kimura T; Saruwatari K; Saeki S; Ichiyasu H; Fujii K; Tomita Y
Immun Inflamm Dis; 2019 Mar; 7(1):3-6. PubMed ID: 30461210
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
19. Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Uchibori K; Yanagitani N; Horiike A; Horai T; Seike M; Gemma A; Nishio M
BMC Cancer; 2020 Mar; 20(1):207. PubMed ID: 32164651
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]